Sunovion's Seizure Drug Aptiom Wins Monotherapy Use

Marlborough, Massachusetts-based Sunovion Pharmaceuticals won the FDA's approval to market Aptiom (eslicarbazepine acetate) as monotherapy to treat partial-onset seizures.

More from Neurological

More from Therapy Areas